A detailed history of Barclays PLC transactions in Nektar Therapeutics stock. As of the latest transaction made, Barclays PLC holds 358,294 shares of NKTR stock, worth $326,047. This represents 0.0% of its overall portfolio holdings.

Number of Shares
358,294
Previous 358,294 -0.0%
Holding current value
$326,047
Previous $466,000 -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 15, 2024

BUY
$1.11 - $1.48 $194,911 - $259,882
175,596 Added 96.11%
358,294 $466,000
Q2 2024

Aug 14, 2024

SELL
$0.9 - $1.83 $351,249 - $714,206
-390,277 Reduced 68.11%
182,698 $227,000
Q1 2024

May 15, 2024

BUY
$0.49 - $0.96 $2,485 - $4,870
5,073 Added 0.89%
572,975 $535,000
Q4 2023

Feb 15, 2024

BUY
$0.42 - $0.57 $141,985 - $192,694
338,061 Added 147.08%
567,902 $321,000
Q3 2023

Nov 07, 2023

BUY
$0.51 - $1.05 $87,979 - $181,134
172,509 Added 300.89%
229,841 $137,000
Q2 2023

Aug 03, 2023

SELL
$0.53 - $1.03 $50,573 - $98,284
-95,422 Reduced 62.47%
57,332 $33,000
Q1 2023

May 04, 2023

SELL
$0.64 - $3.15 $7,133 - $35,109
-11,146 Reduced 6.8%
152,754 $108,000
Q4 2022

Feb 13, 2023

BUY
$2.03 - $4.28 $39,475 - $83,228
19,446 Added 13.46%
163,900 $372,000
Q3 2022

Nov 03, 2022

SELL
$3.04 - $5.14 $337,689 - $570,961
-111,082 Reduced 43.47%
144,454 $463,000
Q2 2022

Aug 12, 2022

BUY
$3.17 - $6.17 $201,507 - $392,208
63,567 Added 33.11%
255,536 $971,000
Q1 2022

May 16, 2022

BUY
$4.16 - $13.72 $472,642 - $1.56 Million
113,616 Added 145.01%
191,969 $1.04 Million
Q4 2021

Feb 14, 2022

SELL
$10.83 - $18.41 $665,622 - $1.13 Million
-61,461 Reduced 43.96%
78,353 $1.06 Million
Q3 2021

Nov 09, 2021

SELL
$13.07 - $18.84 $909,005 - $1.31 Million
-69,549 Reduced 33.22%
139,814 $2.51 Million
Q2 2021

Aug 13, 2021

BUY
$16.52 - $20.4 $3.17 Million - $3.91 Million
191,836 Added 1094.52%
209,363 $3.59 Million
Q1 2021

May 13, 2021

SELL
$16.56 - $25.46 $310,119 - $476,789
-18,727 Reduced 51.65%
17,527 $350,000
Q4 2020

Feb 11, 2021

SELL
$15.77 - $19.03 $2.69 Million - $3.24 Million
-170,356 Reduced 82.45%
36,254 $616,000
Q3 2020

Nov 12, 2020

SELL
$16.59 - $24.79 $695,038 - $1.04 Million
-41,895 Reduced 16.86%
206,610 $3.43 Million
Q2 2020

Aug 12, 2020

SELL
$16.86 - $23.44 $1.7 Million - $2.37 Million
-100,970 Reduced 28.89%
248,505 $5.76 Million
Q1 2020

May 13, 2020

BUY
$14.47 - $27.96 $2.7 Million - $5.23 Million
186,915 Added 114.98%
349,475 $6.24 Million
Q4 2019

Feb 10, 2020

SELL
$15.87 - $23.12 $5.29 Million - $7.71 Million
-333,434 Reduced 67.23%
162,560 $3.51 Million
Q3 2019

Nov 14, 2019

BUY
$16.91 - $36.27 $4.15 Million - $8.9 Million
245,477 Added 97.99%
495,994 $9.03 Million
Q2 2019

Aug 14, 2019

BUY
$31.0 - $36.3 $918,840 - $1.08 Million
29,640 Added 13.42%
250,517 $8.91 Million
Q1 2019

May 15, 2019

BUY
$31.58 - $46.35 $133,299 - $195,643
4,221 Added 1.95%
220,877 $7.42 Million
Q4 2018

Feb 14, 2019

SELL
$30.43 - $56.65 $2.21 Million - $4.12 Million
-72,700 Reduced 25.12%
216,656 $7.12 Million
Q3 2018

Nov 14, 2018

SELL
$46.46 - $68.49 $5.3 Million - $7.82 Million
-114,147 Reduced 28.29%
289,356 $17.6 Million
Q2 2018

Aug 14, 2018

BUY
$46.25 - $104.45 $5.53 Million - $12.5 Million
119,670 Added 42.16%
403,503 $19.7 Million
Q1 2018

May 15, 2018

SELL
$57.4 - $108.44 $6.08 Million - $11.5 Million
-105,979 Reduced 27.19%
283,833 $30.2 Million
Q4 2017

Feb 14, 2018

BUY
$23.02 - $60.5 $3.63 Million - $9.55 Million
157,880 Added 68.07%
389,812 $23.3 Million
Q3 2017

Nov 14, 2017

BUY
$17.79 - $24.0 $4.13 Million - $5.57 Million
231,932
231,932 $5.57 Million

Others Institutions Holding NKTR

About NEKTAR THERAPEUTICS


  • Ticker NKTR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 187,404,992
  • Market Cap $171M
  • Description
  • Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...
More about NKTR
Track This Portfolio

Track Barclays PLC Portfolio

Follow Barclays PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.